Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA
A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA

NCT03000439

CompletedPhase 3

Sponsor: Pfizer

Conditions: Arthritis Juvenile Idiopathic

Interventions: In open-label phase: treatment with tofacitinib, In double-blind phase: treatment with tofacitinib or placebo in 1:1 ratio

Countries: United States, Argentina, Belgium, Brazil, Canada, China, Costa Rica, Germany

A randomized withdrawal study in which responders to open-label treatment with tofacitinib will be randomized in a 1:1 ratio to tofacitinib or placebo in a double-blind phase. In the double-blind phase "time to sJIA flare" will be evaluated as primary endpoint and subjects will be discontinued once they experience sJIA flare. An interim analysis for efficacy and futility will be conducted when at least 20 flares have been observed. If either criterion is met, the study will be stopped. If neither criterion is met, the study will continue until the requisite number of flares are observed as determined by the number of flares included in the interim analysis and a statistical penalty for conducting the interim analysis.

Eligibility overview

Sex: ALL

Age: 2 Years to 17 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* active sJIA disease according to ILAR criteria before screening and at baseline (Day 1);
* Treatment with stable doses of methotrexate (MTX) ≤25 mg/week or ≤20 mg/m2/week, whichever is lower, is permitted;
* Treatment with a stable dose of oral prednisone ≤1 mg/kg/day up to a maximum of 30 mg/day, or equivalent, for at least 1 week before the first study drug dose is permitted.

Exclusion Criteria:

* Previous juvenile idiopathic arthritis (JIA) treatment with tofacitinib.
* Current symptoms or findings of myocarditis, endocarditis or more than minimal pericardial effusion associated with systemic juvenile idiopathic arthritis (sJIA). Current symptoms or findings of more than minimal pleuritis with sJIA.
* Current infection or serious infection within 3 months of study enrollment.
Locations (52)
  • Phoenix, Arizona, United States
  • Los Angeles, California, United States
  • Chicago, Illinois, United States
  • Lake Success, New York, United States
  • New Hyde Park, New York, United States
  • Rosario, Santa Fe Province, Argentina
  • San Miguel de Tucumán, Tucumán Province, Argentina
  • Ghent, Belgium
  • Botucatu, São Paulo, Brazil
  • Botucatu, São Paulo, Brazil
  • São Paulo, Brazil
  • São Paulo, Brazil
  • São Paulo, Brazil
  • Calgary, Alberta, Canada
  • Montreal, Quebec, Canada
  • Chongqing, Chongqing Municipality, China
  • Guangzhou, Guangdong, China
  • Wuhan, Hubei, China
  • Changsha, Hunan, China
  • Suzhou, Jiangsu, China
  • Xi'an, Shaanxi, China
  • Chengdu, Sichuan, China
  • Hangzhou, Zhejiang, China
  • Beijing, China
  • San José, Costa Rica
  • Erlangen, Bavaria, Germany
  • Sendenhorst, Germany
  • Budapest, Hungary
  • Surat, Gujarat, India
  • Rajinder Nagar, NEW Delhi, India
  • + 22 more on CT.gov